GO
Loading...

Pharmaceuticals

More

  • Johnson & Johnson

    Can we please get some upside earnings reports this quarter? No financial exposure here. Instead, this Dow Industrial has plenty of overseas business to be helped by the weaker dollar and guardedly optimistic expectations for key business segments.

  • Hospital Equipment Makers: Are They In The ER? Monday, 14 Apr 2008 | 11:40 AM ET
    GE

    On Friday I did a sidebar story on what might be ailing General Electric's healthcare business. (Disclosure: CNBC is owned by NBC Universal, which is a unit of GE). It was responsible for a penny of the earnings miss. On "Squawk Box" that morning CEO Jeff Immelt said the longer-than-expected closure of a manufacturing plant was partially to blame.

  • I know that a number of pharma and biotech PR people read this blog, so I wanted to hold up the Genentech earnings release as what I think is a great example of user-friendliness. It is really heads and shoulders above the quarterly communications that come out of most of the companies I cover.

  • MannKind Being Its Own "Man" About Inhalable Insulin Thursday, 10 Apr 2008 | 12:22 PM ET

    This morning there's a plethora of stuff to blog about: the Takeda-Millennium deal, more commentary about Merck and Schering-Plough and the extent of the Vytorin/Zetia fallout, Genentech's biotech bellweather earnings after the closing bell today, just to name a few.

  • Japan's Takeda to Buy Millennium Pharma Thursday, 10 Apr 2008 | 6:25 AM ET

    Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.

  • Merck: Cramer's No. 1 Dow Stock Wednesday, 9 Apr 2008 | 7:08 PM ET

    He's expecting a full recovery – and more – for this company.

  • Pfizer Adds Lung Cancer Warning to Exubera Insulin Wednesday, 9 Apr 2008 | 10:51 AM ET

    Pfizer and Nektar Therapeutics said Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.

  • CNBC and other media outlets have done a significant amount of reporting on cardiologists' reaction to the Vytorin/Zetia study and the effect the ACC panel's opinion might have on the heart doctors' prescription writing.

  • European Earnings to Hold Up in First Quarter Wednesday, 9 Apr 2008 | 6:25 AM ET

    European corporate profits for the first quarter of 2008 are expected to hold up, but weaker economic growth resulting from the credit crisis and a stronger euro will take their toll on earnings later in the year.

  • Antigenics Finds That "Russian Roulette" Pays Off Tuesday, 8 Apr 2008 | 10:31 AM ET

    This morning a little biotech company, Antigenics, announced that Russia has approved its kidney cancer drug Oncophage. It's the first so-called therapeutic cancer vaccine to win full-out approval anywhere in the world.

  • TPG Buying Half of Russian Drug Distributor: WSJ Tuesday, 8 Apr 2008 | 2:03 AM ET

    U.S. private equity firm TPG is planning to announce that it is buying half of SIA  Iternational, Russia's largest pharmaceutical distributor, for $800 million, the Wall Street Journal reported on its Web site.

  • Alzheimer's Miracle? Monday, 7 Apr 2008 | 6:33 PM ET

    Shares of Wyeth and Elan surged Monday on the promise of a new Alzheimer's drug. Can you trade it?

  • Euro Stocks End Higher as Miners, Banks Gain Monday, 7 Apr 2008 | 12:34 PM ET

    European shares advanced on Monday, adding to last week's gains, led by financials such as Swiss bank UBS and mining stocks, which gained on the back of higher metals prices and an upbeat analyst note.

  • Schering-Plough And The Vytorin-Zetia Backstory Monday, 7 Apr 2008 | 11:31 AM ET

    The Star-Ledger of New Jersey this weekend did a story that I think provides the best insight and backstory about what happened last week at the highest levels of Schering-Plough.CEO Fred Hassan was in Miami when doctors dropped the bomb on Vytorin and Zetia at the American College of Cardiology meeting.

  • Schering-Plough's Hell Week Friday, 4 Apr 2008 | 7:58 PM ET

    CEO Fred Hassan updates investors on his company's plans to rebound from the Vytorin debacle.

  • My Merck/Schering-Plough Coverage Draws Your Emails Friday, 4 Apr 2008 | 5:02 PM ET

    This week started out with Merck shares suffering their worst loss since the day the drugmaker recalled Vioxx and Schering-Plough shares posting their worst one-day decline ever. But yesterday, SGP had its biggest percentage gain in eight years and today it's finishing the week as the sector's biggest percentage gainer.

  • Pfizer's Viagra

    Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.

  • Dendreon's Secret "Lover"--With A Strong Ticker Thursday, 3 Apr 2008 | 4:02 PM ET

    The small biotech company Dendreon put out a press release this morning announcing that an unidentified institutional investor is going to buy eight million shares and warrants to buy as much as another eight million for a total infusion of $47 million.

  • Amgen's Bone Drug Data: Is There "Bone Of Contention"? Thursday, 3 Apr 2008 | 11:05 AM ET
    AMGEN

    After the closing bell yesterday, Amgen put out a press release announcing that phase 3 pivotal data are being published in a scientific/medical journal about its most important drug development pipeline product--an osteoporosis drug known as D-mab. (Whenever you see the letters mab at the end of the scientific name for a drug it means it's a monoclonal antibody).

  • Options Look to Hepatitis-C Payoff Thursday, 3 Apr 2008 | 9:40 AM ET

    Options activity is picking up in Johnson & Johnson stock. Why?